10-K: Arcus Biosciences Navigates Clinical Setbacks, Bolsters Capital

Arcus Biosciences reports increased net losses in 2025, discontinues a Phase 3 trial, but strengthens its financial position with new equity and debt financing.

Summary

• Net loss increased to $353 million in 2025, up from $283 million in 2024, with an accumulated deficit of $1.5 billion as of December 31, 2025.
• Total revenues decreased to $247 million in 2025 from $258 million in 2024, primarily due to lower Taiho collaboration revenue and timing of Gilead collaboration progress.
• Research and Development (R&D) expenses rose to $523 million in 2025 from $448 million in 2024, driven by increased clinical activities for casdatifan and quemliclustat.
• The Phase 3 STAR-221 clinical trial for domvanalimab-based combination in upper gastrointestinal cancers was discontinued in December 2025 due to futility, along with the Phase 2 EDGE-Gastric study.
• Taiho Pharmaceutical Co., Ltd. exercised its option for an exclusive license to casdatifan in Japan and certain other Asian territories (excluding mainland China) in October 2025, including a $15 million option exercise payment.
• Updated data from the Phase 1/1b ARC-20 study showed casdatifan monotherapy achieved a median Progression-Free Survival (mPFS) of 15.1 months for the 100mg QD cohort in late-line metastatic kidney cancer, compared to 5.6 months for Merck's belzutifan.
• Recruitment for the eVOLVE-RCC02 study (casdatifan plus volrustomig) was temporarily paused due to observations of potentially immune-mediated adverse events.
• Enrollment for the Phase 3 PRISM-1 study (quemliclustat in pancreatic cancer) was completed in September 2025, with results expected in the first half of 2027.
• Quemliclustat received Orphan Drug Designation from the FDA for the treatment of pancreatic cancer in July 2025.
• Future development of etrumadenant was paused in Q1 2025, and Gilead returned its license for the adenosine receptor antagonist program in June 2025.
• Cash, cash equivalents, and marketable securities totaled $1.0 billion as of December 31, 2025, projected to fund operations until at least the second half of 2028.
• The company issued 29.4 million shares of common stock through underwritten offerings and an at-the-market facility in 2025, generating approximately $438 million in gross proceeds.
• An additional $50 million was drawn from the Hercules Capital loan facility in Q2 2025, and the agreement was amended in December 2025 to extend the maturity date to September 1, 2030, and modify covenants.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed bag. While the company successfully raised significant capital and showed promising data for casdatifan, the discontinuation of a late-stage Phase 3 trial for domvanalimab and the pause in another casdatifan study represent significant clinical setbacks and increased financial burn, tempering overall sentiment.

Positives

• Taiho Pharmaceutical Co., Ltd. exercised its option for casdatifan, providing a $15 million option exercise payment and potential future milestones and royalties.
• Casdatifan monotherapy in the Phase 1/1b ARC-20 study demonstrated a median Progression-Free Survival (mPFS) of 15.1 months, significantly outperforming Merck's approved HIF-2 inhibitor, belzutifan (5.6 months mPFS), in a similar patient population.
• Quemliclustat received Orphan Drug Designation from the FDA for pancreatic cancer, which may provide financial incentives and market exclusivity if approved.
• The Phase 3 PRISM-1 study for quemliclustat in pancreatic cancer completed enrollment rapidly within 12 months of initiation, indicating efficient trial execution.
• The company maintains a strong liquidity position with $1.0 billion in cash, cash equivalents, and marketable securities, expected to fund operations until at least the second half of 2028.
• Successful capital raises in 2025 through equity offerings generated approximately $438 million in gross proceeds, bolstering the company's financial runway.
• The Hercules Capital loan agreement was amended to extend the maturity date to September 1, 2030, providing longer-term debt financing and flexibility.

Negatives

• Net loss increased to $353 million in 2025 from $283 million in 2024, indicating a worsening financial performance.
• Total revenues decreased in 2025 compared to 2024, reflecting reduced collaboration income.
• The Phase 3 STAR-221 study for domvanalimab was discontinued due to futility, representing a significant clinical setback for a late-stage asset.
• The Phase 2 EDGE-Gastric study was also discontinued following the STAR-221 futility outcome.
• Recruitment for the eVOLVE-RCC02 study (casdatifan + volrustomig) was temporarily paused due to observations of potentially immune-mediated adverse events.
• The decision to pause future development of etrumadenant and Gilead's return of its license for the program indicates a pipeline reduction.
• Research and Development expenses increased in 2025, contributing to higher operating losses.
• Partnership reimbursements decreased in 2025, suggesting the company is bearing a larger share of development costs for certain programs.

Risks

• History of operating losses and no revenue from product sales; anticipates significant losses for the foreseeable future.
• Need to obtain additional funding; inability to raise capital could force restriction or elimination of product development programs.
• Operating activities may be restricted by covenants under the Hercules Agreement; default could require immediate repayment.
• Inability to obtain regulatory approval for investigational products or significant delays in doing so.
• Preliminary, topline, and interim clinical data are subject to audit and verification, potentially resulting in material changes in final data.
• Enrollment and retention of subjects in clinical trials are expensive, time-consuming, and can be made difficult by competing treatments, geopolitical instability, and public health epidemics.
• Serious adverse events, undesirable side effects, or other unexpected properties of investigational products may lead to discontinuation of development programs or limitations on use.
• Certain investigational products may require companion diagnostics; failure to successfully develop, validate, and obtain regulatory clearance or approval for such tests could harm product development strategy.
• Dependence on the collaboration with Gilead for research, development, manufacture, and commercialization of certain investigational products; if unsuccessful, business could be adversely affected.
• Reliance on third parties (CROs, clinical investigators, manufacturers) to conduct clinical trials and perform research/preclinical studies; failure to perform could cause delays or increased costs.
• Even if marketing approval is received, commercialization of investigational products may not be successful.
• Commercial success is dependent on obtaining coverage and reimbursement from government or other third-party payors, which may be delayed or insufficient.
• Obtaining regulatory approval in one jurisdiction does not guarantee approval in any other jurisdiction.
• Investigational products intended for approval as biologic products may face competition sooner than anticipated from biosimilars.
• Breach of obligations under in-license agreements may require payment of damages or loss of rights to investigational products.
• Inability to obtain and maintain sufficient intellectual property protection for investigational products, or if the scope of protection is not broad enough, competitors could commercialize similar products.
• Risk of involvement in lawsuits alleging infringement of third-party intellectual property rights or to protect/enforce patents, which could be expensive and time-consuming.
• Changes in patent law in the U.S. and other jurisdictions could diminish the value of patents.
• Reliance on trade secrets and proprietary know-how, which can be difficult to trace and enforce; inability to protect confidentiality could harm competitive position.
• Expansion of business operations may lead to difficulties in managing growth.
• Substantial competition from other pharmaceutical and biotechnology companies.
• Internal information technology systems and those of third-party CROs are subject to failure, security breaches, and other disruptions.
• Failure to comply with data privacy and data protection laws, regulations, or other obligations could lead to government enforcement actions, private litigation, and/or adverse publicity.
• Changes in healthcare law and implementing regulations, as well as changes in healthcare policy, may impact the business in unpredictable ways.
• Exposure to U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations.
• Adverse effects from earthquakes, fires, or other natural disasters, particularly given the concentration of facilities in the San Francisco Bay Area.
• Ability to use net operating loss carryforwards and certain other tax attributes may be limited.
• Changes in tax laws and regulations or exposure to additional tax liabilities could adversely affect financial results.
• Product liability lawsuits against the company could cause substantial liabilities and limit commercialization.
• The stock price of common stock has been and may continue to be volatile or may decline regardless of operating performance.
• Quarterly operating results may fluctuate significantly or fall below expectations, causing stock price to fluctuate or decline.
• Concentration of stock ownership (e.g., Gilead's 25.1%) limits other stockholders' ability to influence corporate matters.
• Delaware law and provisions in the company's certificate of incorporation and bylaws could make a merger, tender offer, or proxy contest difficult.
• Sales of substantial amounts of shares may cause the price of common stock to decline.
• Failure to maintain proper and effective internal controls could impair the ability to produce accurate and timely financial statements.

Future Outlook

The company expects to incur substantial and increasing operating losses for the foreseeable future as it advances its investigational products. Its current cash, cash equivalents, and marketable securities of $1.0 billion are projected to fund planned operations until at least the second half of 2028. R&D expenses are anticipated to decrease in the near-term due to the wind-down of domvanalimab studies, partially offset by increased investment in casdatifan and inflammation/immunology programs. The company aims to advance its first inflammation development candidate into the clinic in 2026, initiate a second Phase 3 study for casdatifan in first-line ccRCC by the end of 2026, and expects results from the PRISM-1 study in the first half of 2027. An IND filing for the TNF program molecule is targeted for late 2026 or early 2027, and a futility analysis for STAR-121 is expected in Q1 2026.

Management Comments

• Our vision is to leverage our internal small-molecule discovery capabilities to create, develop and commercialize highly differentiated therapies that can have a meaningful impact on patients.
• Our goal for casdatifan is to leverage the potential best-in-class efficacy profile and maximize the opportunity for casdatifan by developing this molecule across multiple settings and with optimal combination partners.
• The strategy for casdatifan in first-line ccRCC capitalizes on the strong desire by clinicians and patients to avoid TKIs and their associated toxicities.
• We believe that inhibiting MRGPRX2 may offer several advantages over other approaches for the treatment of CSU, including the ability to treat patients whose disease is not primarily driven by IgE, oral administration, greater specificity for mast cells, and fewer side effects such as neutropenia and hair depigmentation.
• We believe there is currently only one other small-molecule TNF inhibitor in clinical development, demonstrating the difficulty of developing highly potent and selective small molecules against this target.
• The drug discovery and development experience, and overall biopharmaceutical company management experience of Drs. Rosen and Jaen, would be difficult to replace.

Industry Context

StockSavvy.ai notes that the biopharmaceutical industry is characterized by rapidly advancing technologies and intense competition. The company's focus on small-molecule discovery for oncology and inflammation/autoimmune diseases aligns with industry trends seeking differentiated therapies. The discontinuation of the STAR-221 trial highlights the inherent risks in late-stage clinical development, even with promising early data, a common challenge in the sector. The competitive landscape for HIF-2 inhibitors, TIGIT antibodies, and CD73 inhibitors is robust, with several large pharmaceutical companies and other biotechs developing competing assets. The company's strategy to develop best-in-class oral small molecules to displace injectable biologics in inflammation is a significant trend in the industry.

Comparison to Industry Standards

• Casdatifan monotherapy in the ARC-20 study demonstrated a median Progression-Free Survival (mPFS) of 15.1 months for the 100mg QD cohort, significantly exceeding the 5.6 months mPFS reported for Merck & Co., Inc.'s belzutifan (an approved HIF-2 inhibitor) in its Phase 3 registrational trial LITESPARK-005 in a similar patient population.
• The discontinuation of the Phase 3 STAR-221 study for domvanalimab due to futility, despite earlier Phase 2 EDGE-Gastric data showing median overall survival (OS) beyond two years (exceeding benchmarks of 13-14 months from other Phase 3 studies), illustrates the high attrition rate and unpredictability of late-stage oncology trials, which is a common industry challenge.
• The company's goal to develop best-in-class, oral, small-molecule drugs to displace injectable biologics for inflammatory and autoimmune diseases positions it against established products like Sanofi and Regeneron's Dupixent, Genentech and Novartis' Xolair, and Abbvie's Humira.
• The company notes only one other small-molecule TNF inhibitor in clinical development, indicating the high difficulty and potential differentiation of its TNF program compared to the broader market dominated by injectable anti-TNF biologics.

Corporate Governance

Legal Proceedings

• Not currently a party to any material legal proceedings.

Related Party Transactions

• Gilead Sciences, Inc. is a significant collaboration partner and held approximately 25.1% of outstanding common stock as of December 31, 2025.
• Gilead has the right to designate three members to the board of directors, which they have exercised.
• Revenue from Gilead under collaboration agreements was $240 million in 2025, $243 million in 2024, and $112 million in 2023.
• Net expense to Gilead of $30 million was recognized in 2025; net reimbursements from Gilead were $37 million in 2024 and $110 million in 2023.
• A net payable to Gilead of $24 million was recorded in Accounts payable as of December 31, 2025.
• Gilead purchased 1.4 million shares of common stock for $15 million in Q1 2025 as part of an underwritten offering.
• Taiho Pharmaceutical Co., Ltd. exercised its option for an exclusive license to casdatifan in Q4 2025, resulting in a $15 million option exercise payment.
• Reimbursements from Taiho for R&D expenses, including advance cost share payments, were $34 million in 2025, $28 million in 2024, and $8 million in 2023.
• A net receivable from Taiho of $10 million was recorded in Receivable from collaboration partners as of December 31, 2025.
• A liability of $44 million related to certain advance cost sharing payments under the Taiho arrangement was recorded in Other liabilities as of December 31, 2025.

Stakeholder Impact

• Shareholders: Potential for stock price volatility due to clinical trial outcomes (e.g., STAR-221 discontinuation), dilution from recent equity offerings, and the significant influence of major stockholders like Gilead.
• Employees: Impact of R&D program changes (e.g., discontinuation of STAR-221, pausing etrumadenant) on job security or focus, continued opportunities for growth and development, and competitive compensation and benefits.
• Customers/Patients: Potential for new differentiated therapies in cancer and inflammatory diseases, but also setbacks (e.g., STAR-221 futility) affecting future treatment options and availability.
• Partners (Gilead, Taiho, AstraZeneca): Continued collaboration, shared development costs, milestone payments, and potential royalties, with specific impacts from option exercises and program changes.
• Creditors (Hercules Capital): The loan is secured by substantially all assets, and adherence to financial and operational covenants is critical to avoid default and potential acceleration of debt repayment.

Next Steps

• Futility analysis for STAR-121 (domvanalimab in NSCLC) expected in Q1 2026.
• Expects to identify lead development candidate for TNF program in early 2026.
• Expects to advance first development candidate from inflammation programs into the clinic in 2026.
• Expects to initiate first study for MRGPRX2 inhibitor in healthy volunteers in 2026.
• Targets initiation of a second Phase 3 study for casdatifan in first-line ccRCC by the end of 2026.
• Expects to file an IND for TNF program molecule in late 2026 or early 2027.
• Results from PRISM-1 study (quemliclustat in pancreatic cancer) expected in the first half of 2027.
• Continue to monitor participants in eVOLVE-RCC02 to further characterize the safety profile of the combination.
• Deliver example of revenue shortfall calculations within 30 days of the First Amendment Closing Date (December 18, 2025).
• Deliver a secretary's certificate to Agent dated as of the First Amendment Closing Date.
• Pay an amendment fee of $150,000 and all reasonable Lender expenses to Agent.
• Deliver duly executed landlord consents and bailee agreements within 45 days following the Closing Date (or later date as Agent may agree).
• Deliver duly executed Account Control Agreement(s) within 15 days following the Closing Date (or later date as Agent may agree).
• Deliver security documentation for Borrower's Deposit Account ending in 9075 maintained with JPMorgan Ireland within 90 days following the Closing Date (or later date as Agent may agree).
• Deliver insurance endorsements within 30 days following the Closing Date (or later date as Agent may agree).
• Deliver duly executed and completed SBA Form 1031 within 3 days following the Closing Date (or later date as Agent may agree).
• Notify Agent of each Subsidiary formed or acquired subsequent to the Closing Date within 45 days of such formation or acquisition.
• Notify Agent promptly (within 3 Business Days) of certain regulatory notices or actions.
• Notify Agent promptly (within 3 Business Days) of the occurrence of any Event of Default.
• Notify Agent immediately of any failure to comply with SBA obligations.
• Give prompt written notice to Agent of entering into or materially amending or terminating a Material Agreement.
• Provide written notice to Agent concurrently with the delivery of each Compliance Certificate of any new Patent, registered Trademark, registered Copyright, registered mask work, or any pending application for any of the foregoing.
• Provide to Agent application numbers, application dates, and registration numbers for applications for Patents or for the registration of Trademarks, Copyrights or mask works, together with each Compliance Certificate.

Key Dates

Recommendation

The company faces significant clinical setbacks with the discontinuation of a Phase 3 trial and the pausing of another, leading to increased net losses. However, it has successfully raised substantial capital and secured an extended debt maturity, providing liquidity until at least H2 2028. The promising casdatifan data against an approved competitor offers a potential upside, but the overall pipeline has experienced mixed results. Given the high-risk nature of biopharmaceutical development, the current situation warrants a 'hold' as investors await further clarity on the remaining clinical programs and the path to profitability.

Keywords

Biopharmaceutical, Oncology, Inflammation, Autoimmune Diseases, Clinical Trials, Phase 3, HIF-2 Inhibitor, Casdatifan, CD73 Inhibitor, Quemliclustat, TIGIT Antibody, Domvanalimab, PD-1 Antibody, Zimberelimab, Gilead Collaboration, Taiho Agreement, Hercules Capital, Drug Development, Regulatory Approval, Biotech, Pharmaceutical, Cancer Treatment, Renal Cell Carcinoma, Pancreatic Cancer, NSCLC, Immuno-oncology, Small Molecule, Biologics, SEC Filing, 10-K